Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD
Shots:
- The US FDA has granted orphan drug designation to the company’s AND017 for the treatment of Sickle Cell Disease (SCD)
- P-I&II studies results for AND017 to treat anemia in NDD-CKD & DD-CKD are being presented at the ASN Kidney Week in San Diego. Non-clinical data supports AND017’s ODD for SCD will be presented in future scientific meetings and also be published in a scientific journal later on
- AND017 (HbEA) that works on multiple stages of the RBC life cycle. It is being developed to treat various types of anemia, including those associated with DD-CKD, NDD-CKD, CRA, MDS anemia, SCD, and β-thalassemia.
Ref: PR Newswire | Image: Kind Pharmaceuticals
Related News:- Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
